RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 BOW-015 is Biosimilar to Infliximab with Respect to Efficacy and Safety
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 17
SP 17
OP 18
DO 10.1177/155989771417009
UL http://mdc.sagepub.com/content/14/17/17.2.abstract
AB Infliximab was the first anti—tumor necrosis factor a monoclonal antibody approved for the treatment of rheumatoid arthritis (RA). In 2013, CT-P13 was the first infliximab biosimilar agent approved by the European Commission. This Phase 3 trial of BOW-015 is the first study to compare an infliximab biosimilar agent with infliximab in patients with RA, assessing time points before Week 14.